Case study shows how one CRO ensured high-quality, consistent data in a difficult therapeutic area.
Work across varying therapeutic areas and new technology among reasons why CROs are qualified to advance model.
Wednesday, October 12, 2022 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Real-world-data (RWD) leads to real-world results. Learn how RWD & patient tokenization are streamlining clinical trials and ensuring successful results.
Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.
Changes predicted to change the face of clinical research in 2021.
Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Integrated approaches can help enhance recruitment plans.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
The careful selection of sensor technology prioritized in clinical trials, considering regulatory compliance, data security, device characteristics, and the specific needs of the trials for successful and confident implementation.
In an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
Study seeks to understand how different forms of data meet the needs of researchers.
Addressing data integrity and compliance concerns.
Strategic AI applications are helping life sciences teams overcome hidden bias, accelerate data discovery, and improve evidence integrity at the start of the pipeline.
Implementing disclosure and data transparency policies and procedures represents an opportunity for sponsors, rather than an obligation.
Improving the site-sponsor relationship can get trials off on the right foot and on a path for success.
Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
The current lack of clinical trial professionals is a serious concern that's compromising the ability to conduct high-quality clinical trials, but it's not irreversible.
Trust-based relationships form the foundation for successful trial management.
Advances in technology open door for improved EHR to EDC transfer process.
Latest CISCRP study provides insight on proactive outreach.
Capacity management and stability offer value for clients, their employees and FSP vendors.
Poll taken by leading biotech executives in clinical development addresses state of data quality and management.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
This article sets out a vision of adopting convenient alternative blood sampling approaches that places the needs of the patient at the center and enables active monitoring, before the onset of clinical events, leading to improved healthcare.
Leveraging artificial intelligence-powered stochastic methods for clinical data review represents a significant leap beyond traditional approaches.
Thursday, September 30, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Give yourself a competitive edge by learning how the world’s leading designer of innovative clinical trials can help you integrate elements of economic theory to your clinical trial design. Optimize sample size, speed, and power by exploring a broader array of designs and quickly identifying those that meet your objectives.
Adjusting to the changing dynamics of the clinical research associate role.
Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.
Why weighing all of the ‘DE&I’ components is critical at site and sponsor levels.
To derive the greatest benefits from eCOA technology, several elements must work together to create a strong foundation for sponsor success.